No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Two leading medical stocks that appear reasonable at current levels are AbbVie (NYSE: ABBV) and Merck (NYSE: MRK). The former ...

Dividend investing rewards patience. The best dividend stocks don’t just pay consistently—they raise payouts year after year, ...

AbbVie (NYSE: ABBV) has the highest share price of any stock on this list, at more than $200 each. But don't let the price ...

Lastly, AbbVie is a fantastic income stock. The company is part of the group of Dividend Kings, corporations that have ...

“We sit in the low 60s in terms of Botox share, and that's a clear leadership position by a large margin in the U.S.,” AbbVie ...

Mark Manfredi brings over two decades of international biopharmaceutical industry leadership and cancer drug discovery success to DISCOFinancing ...

Discover why AbbVie (ABBV) is rated Strong Buy, with robust 2025 growth, diversified revenues, and attractive valuation.

AbbVie Inc. (NYSE: ABBV) garnered a ‘Buy’ rating from analyst Rajesh Kumar at HSBC, suggesting a robust upside potential for investors. The analyst set a price target of $265, indicating a notable ...

Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, ...

Biogen (BIIB) stock slips as HSBC downgrades to a Sell equivalent rating as part of an analysis that included an upgrade on ...

HSBC analyst Rajesh Kumar upgraded AbbVie Inc. (NYSE: ABBV) from Hold to Buy and boosted the price target from $225 to $265.